Clinical Validation Study for iVue
NCT01242553 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 48
Last updated 2017-09-28
Summary
To demonstrate clinical substantial equivalence of iVue as comparable to commercially available RTVue.
Conditions
- Normal and Ocular Pathology
Sponsors & Collaborators
-
Optovue
lead INDUSTRY
Principal Investigators
-
Michael Hee, MD · Pacific Eye Specialists
-
Nalin Mehta, MD · Colorado Retina Center
-
Michael Sinai, PhD · Optovue
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2009-10-31
- Primary Completion
- 2010-09-30
- Completion
- 2010-09-30
Countries
- United States
Study Locations
More Related Trials
-
Study to Assess the EffectiVeness of exIsting Anti-vascular Endothelial groWth Factor (Anti-VEGF) Treatment Regimens in Patients With Wet Age-related Macular Degeneration
NCT01933152 ·Status: COMPLETED
-
An Evaluation of Safety and Efficacy of Anecortave Acetate Versus Placebo in Patients With Subfoveal CNV Due to Exudative AMD
NCT00058994 ·Status: COMPLETED ·Phase: PHASE3
-
SD-OCT-guided Intravitreal Ranibizumab Treatment in Choroidal Neovascularization Due to Myopia
NCT03409250 ·Status: COMPLETED ·Phase: PHASE4
-
Study Comparing Ranibizumab Monotherapy With Combined Verteporfin Therapy in Subfoveal CNV
NCT00429962 ·Status: COMPLETED ·Phase: PHASE3
-
Real-world Evaluation of BEOVU (Brolucizumab) Effectiveness and Durability for Treatment of Neovascular (Wet) Age-related Macular Degeneration (AMD)
NCT06184360 ·Status: COMPLETED
-
Lucentis Utilizing Visudyne (LUV Trial) Combination Therapy in the Treatment of Age-Related Macular Degeneration
NCT00423189 ·Status: TERMINATED ·Phase: PHASE4
-
Screening for NEI Clinical Studies
NCT00001734 ·Status: COMPLETED
-
Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis
NCT01848041 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Investigates Improvement in Vision Following Switching From Avastin and Macugen Over to Lucentis
NCT00804934 ·Status: COMPLETED
-
Clinical Evaluation of the RAVI-Guide
NCT02196584 ·Status: COMPLETED
-
Treatment of Patients With Age-Related Macular Degeneration With Anecortave Acetate
NCT00349739 ·Status: NO_LONGER_AVAILABLE
-
Observation of Treatment Patterns With Lucentis in Approved Indications
NCT02194803 ·Status: COMPLETED
-
Safety and Efficacy Study of rAAV.sFlt-1 in Patients With Exudative Age-Related Macular Degeneration
NCT01494805 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Study To Determine Safety/Efficacy of Lucentis For Treatment Of Retinal Angiomatous Proliferation Secondary To Age Related Macular Degeneration
NCT00395707 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Treatment -Resistant Neovascular Age-Related Macular Degeneration
NCT02332941 ·Status: COMPLETED ·Phase: PHASE1
-
A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
NCT03834753 ·Status: COMPLETED ·Phase: PHASE3
-
Safety Tolerability and Efficacy of Intravitreal LMG324 in the Treatment of Neovascular Age-Related Macular Degeneration
NCT02398500 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Study of the Safety and Efficacy of RVL-1201 in the Treatment of Acquired Blepharoptosis
NCT02436759 ·Status: COMPLETED ·Phase: PHASE3
-
Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD.
NCT02321839 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis
NCT00404612 ·Status: COMPLETED ·Phase: PHASE3
-
Variations in Retinal Nerve Fiber Layer Thickness During Uncomplicated Anterior and Intermediate Uveitis
NCT02879084 ·Status: COMPLETED
-
To Assess the Efficacy and Safety of Intravitreal Ranibizumab in People With Vision Loss Due to Macular Edema
NCT01846299 ·Status: COMPLETED ·Phase: PHASE3
-
Assess the Efficacy/Safety of Intravitreal Ranibizumab in Patients With Vision Loss Due to Choroidal Neovascularization.
NCT01840410 ·Status: COMPLETED ·Phase: PHASE3
-
Ranibizumab Short- and Log-term Effects on Retinal Function in wAMD
NCT01269151 ·Status: COMPLETED ·Phase: NA
-
A Study Assessing Corneal Endothelial Cells in Participants With Neovascular Age-related Macular Degeneration (nAMD) Treated With the Port Delivery System With Ranibizumab (PDS)
NCT04853251 ·Status: RECRUITING ·Phase: PHASE4